
## Javier VÄ;zquez-Bourgon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5018606/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	11.0	136
2	Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. American Journal of Psychiatry, 2019, 176, 21-28.	7.2	127
3	Genetic variants associated with longitudinal changes in brain structure across the lifespan. Nature Neuroscience, 2022, 25, 421-432.	14.8	75
4	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry, 2022, 79, 260.	11.0	44
5	Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. JAMA Psychiatry, 2019, 76, 864.	11.0	43
6	Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. International Journal of Neuropsychopharmacology, 2020, 23, 217-229.	2.1	40
7	Main determinants of Global Assessment of Functioning score in schizophrenia: a European multicenter study. Comprehensive Psychiatry, 2005, 46, 440-446.	3.1	36
8	Understanding sex differences in long-term outcomes after a first episode of psychosis. NPJ Schizophrenia, 2020, 6, 33.	3.6	36
9	Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naìve patients with a first-episode of non-affective psychosis. Psychopharmacology, 2018, 235, 245-255.	3.1	30
10	Effects of copy number variations on brain structure and risk for psychiatric illness: Largeâ€scale studies from the <scp>ENIGMA</scp> working groups on <scp>CNVs</scp> . Human Brain Mapping, 2022, 43, 300-328.	3.6	30
11	Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis. Psychiatry Research, 2010, 175, 189-194.	3.3	29
12	Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Frontiers in Pharmacology, 2021, 12, 646701.	3.5	24
13	Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Research, 2011, 185, 286-289.	3.3	23
14	Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Science Advances, 2019, 5, eaau9093.	10.3	22
15	Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 95, 109677.	4.8	20
16	A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. European Neuropsychopharmacology, 2020, 39, 46-55.	0.7	19
17	Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study. Journal of Psychopharmacology, 2019, 33, 284-294.	4.0	18
18	Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone. International Journal of Neuropsychopharmacology, 2018, 21, 1090-1101.	2.1	16

#	Article	IF	CITATIONS
19	Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics. Translational Psychiatry, 2019, 9, 306.	4.8	16
20	A Disrupted-in-Schizophrenia 1 Gene Variant is Associated with Clinical Symptomatology in Patients with First-Episode Psychosis. Psychiatry Investigation, 2014, 11, 186.	1.6	16
21	Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum. Brain, Behavior, and Immunity, 2021, 91, 673-682.	4.1	15
22	Dissecting the functional outcomes of first episode schizophrenia spectrum disorders: a 10-year follow-up study in the PAFIP cohort. Psychological Medicine, 2021, 51, 264-277.	4.5	15
23	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. Schizophrenia Research, 2022, 243, 32-42.	2.0	15
24	Brain grey matter abnormalities in first episode non-affective psychosis patients with suicidal behaviours: The role of neurocognitive functioning. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 102, 109948.	4.8	14
25	The synergetic effect of childhood trauma and recent stressful events in psychosis: associated neurocognitive dysfunction. Acta Psychiatrica Scandinavica, 2020, 141, 43-51.	4.5	13
26	Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. International Journal of Neuropsychopharmacology, 2021, 24, 1-7.	2.1	12
27	Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study. Schizophrenia Research, 2020, 220, 240-247.	2.0	11
28	Virtual Ontogeny of Cortical Growth Preceding Mental Illness. Biological Psychiatry, 2022, 92, 299-313.	1.3	11
29	Intraoperative Identification and Preservation of Verbal Memory in Diffuse Gliomas. Neurosurgery, 2018, 83, 1209-1218.	1.1	9
30	La estimulación cerebral profunda en el trastorno obsesivo-compulsivo refractario al tratamiento: una revisión sistemática. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 37-51.	1.8	9
31	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 157-163.	1.8	9
32	Cross-Modal Recruitment of Auditory and Orofacial Areas During Sign Language in a Deaf Subject. World Neurosurgery, 2017, 105, 1033.e1-1033.e5.	1.3	7
33	Active psychosis and pro-inflammatory cytokines in first-episode of psychosis. Journal of Psychiatric Research, 2021, 134, 150-157.	3.1	7
34	Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial. European Neuropsychopharmacology, 2021, 47, 74-85.	0.7	7
35	Variations in Disrupted-in-Schizophrenia 1 gene modulate long-term longitudinal differences in cortical thickness in patients with a first-episode of psychosis. Brain Imaging and Behavior, 2016, 10, 629-635.	2.1	6
36	Age of onset of Cannabis use and cognitive function in first-episode non-affective psychosis patients: Outcome at three-year follow-up. Schizophrenia Research, 2018, 201, 159-166.	2.0	6

#	Article	IF	CITATIONS
37	Expression and Functionality Study of 9 Toll-Like Receptors in 33 Drug-NaÃ <sup>-</sup> ve Non-Affective First Episode Psychosis Individuals: A 3-Month Study. International Journal of Molecular Sciences, 2020, 21, 6106.	4.1	6
38	Prolactin, metabolic and immune parameters in naÃ⁻ve subjects with a first episode of psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110332.	4.8	6
39	Community alternatives to acute inpatient care for severe psychiatric patients. Actas Espanolas De Psiquiatria, 2012, 40, 323-32.	0.1	6
40	Deep brain stimulation and treatment-resistant obsessive-compulsive disorder: A systematic review. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 37-51.	0.3	5
41	Ten-year course of cognition in first-episode non-affective psychosis patients: PAFIP cohort. Psychological Medicine, 2022, 52, 770-779.	4.5	5
42	Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-NaÃ⁻ve First-Episode Psychosis. International Journal of Neuropsychopharmacology, 2022, 25, 795-806.	2.1	5
43	Effect of DISC1 Polymorphisms on the Long-term Course of Neurocognitive Deficits in Non-affective Psychosis. European Psychiatry, 2015, 30, 861-867.	0.2	4
44	Diferencias en la efectividad clÃnica y funcional, entre trastornos psiquiátricos, de un hospital de dÃa psiquiátrico de agudos para pacientes con enfermedad mental aguda. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 40-49.	1.8	4
45	Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: Rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3). Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 157-163.	0.3	4
46	Predictors of diagnostic stability in brief psychotic disorders: Findings from a 3â€year longitudinal study. Acta Psychiatrica Scandinavica, 2021, 144, 578-588.	4.5	4
47	Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report. Annals of Clinical Psychiatry, 2014, 26, 301-2.	0.6	4
48	Peripheral lymphocyte signaling pathway deficiencies predict treatment response in first-onset drug-naà ve schizophrenia. Brain, Behavior, and Immunity, 2022, 103, 37-49.	4.1	4
49	Disability multilevel modelling in first episodes of psychosis at 3-year follow-up. Schizophrenia Research, 2017, 185, 101-106.	2.0	3
50	Data regarding the effect of cannabis consumption on liver function in the prospective PAFIP cohort of first episode psychosis. Data in Brief, 2019, 27, 104415.	1.0	3
51	Predictors of weight acquisition induced by antipsychotic treatment and its relationship with age in a sample of first episode non-affective psychosis patients: A three-year follow-up study. Schizophrenia Research, 2020, 222, 462-464.	2.0	3
52	A network analysis approach to functioning problems in first psychotic episodes and their relationship with duration of untreated illness: Findings from the PAFIP cohort. Journal of Psychiatric Research, 2021, 136, 483-491.	3.1	3
53	Cognitive reserve as a moderator of outcomes in five clusters of first episode psychosis patients: a 10-year follow-up study of the PAFIP cohort. Psychological Medicine, 2023, 53, 1891-1905.	4.5	3
54	A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research. Schizophrenia Research, 2022, 243, 467-469.	2.0	3

#	Article	IF	CITATIONS
55	Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study. Schizophrenia Research, 2022, 246, 30-38.	2.0	3
56	Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort. Schizophrenia Research, 2021, 232, 28-30.	2.0	2
57	Differences between psychiatric disorders in the clinical and functional effectiveness of an acute psychiatric day hospital, for acutely ill psychiatric patients. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 40-49.	0.3	2
58	The Early Phases of Anxiety Disorders: From Prevention to Treatment. Modern Problems of Pharmacopsychiatry, 2013, 29, 98-110.	2.5	1
59	44 Real World Effectiveness: A 6-month Naturalistic Follow-up Study of Schizophrenia Patients After Switching to Aripiprazole Monohydrate (AOM) Treatment. CNS Spectrums, 2019, 24, 199-200.	1.2	1
60	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 179-180.	1.8	1
61	Stability of schizophrenia diagnosis in a 10â€year longitudinal study on first episode of nonâ€affective psychosis: Conclusions from the PAFIP cohort. Acta Psychiatrica Scandinavica, 2021, 144, 342-357.	4.5	1
62	Chapter 9 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2012, , 103-109.		1
63	Apnea during slow sub-anaesthetic infusion of intravenous ketamine for treatment-resistant depression. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532098149.	2.7	1
64	Metabolic syndrome and related factors in a large sample of antipsychotic naÃ <sup>-</sup> ve patients with first-episode psychosis: 3 years follow-up results from the PAFIP cohort. Revista De PsiquiatrÃa Y Salud Mental, 2023, 16, 175-183.	1.8	1
65	Naturalistic study on the use of clozapine in the early phases of non-affective psychosis: A 10-year follow-up study in the PAFIP-10 cohort. Journal of Psychiatric Research, 2022, 153, 292-299.	3.1	1
66	5-HT2A POLYMORPHISMS AND NEGATIVE SYMPTOMATOLOGY: EVIDENCE OF ASSOCIATION IN FIRST EPISODE PSYCHOSIS PATIENTS. Schizophrenia Research, 2008, 102, 184.	2.0	0
67	SEROTONIN TRANSPORTER POLYMORPHISMS AND EARLY RESPONSE TO ANTIPSYCHOTIC TREATMENT IN FIRST-EPISODE OF PSYCHOSIS. Schizophrenia Research, 2008, 102, 193.	2.0	Ο
68	DISRUPTED IN SCHIZOPHRENIA 1 GENOTYPE AND RESPONSE TO ANTIPSYCHOTICS IN FIRST EPISODE PSYCHOSIS. Schizophrenia Research, 2010, 117, 456.	2.0	0
69	T175. A 10-YEAR LONGITUDINAL STUDY OF GREY MATTER VOLUME IN FIRST EPISODE OF NON-AFFECTIVE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S184-S184.	4.3	Ο
70	F101. CANNABIS USE AND HEPATIC STEATOSIS IN PSYCHOSIS: RESULTS FROM A 3-YEAR LONGITUDINAL STUDY. Schizophrenia Bulletin, 2018, 44, S259-S259.	4.3	0
71	SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S999.	0.7	Ο
72	F55INFLUENCE OF SCHIZOPHRENIA POLYGENIC RISK SCORES ON BRAIN SURFACE: AN EXPLORATORY STUDY IN FIRST EPISODE OF PSYCHOSIS. European Neuropsychopharmacology, 2019, 29, S1139.	0.7	0

#	Article	IF	CITATIONS
73	Data regarding active psychosis and functional outcome, among other clinical variables, during early phases of the illness in first-episode psychosis in the PAFIP 10-year follow-up program. Data in Brief, 2020, 30, 105599.	1.0	Ο
74	Predictive value of prolactin in first episode psychosis at ten years follow-up. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 179-180.	0.3	0
75	Chapter 10 5-HT2A Polymorphisms and Negative Symptoms Response to Antipsychotic Treatment: Evidence of Association in First-Episode Psychosis Patients. , 2013, , 107-113.		Ο
76	Recovery of long-term paresis following resection of WHO grade II gliomas infiltrating the pyramidal pathway. Journal of Neurosurgical Sciences, 2016, 61, 88-96.	0.6	0
77	Incidence of COPD in a sample of patients with psychosis: preliminary data from a 10 years longitudinal study. , 2019, , .		Ο
78	Reduced glomerular filter rate in antipsychotic-naÃ <sup>-</sup> ve patients with first-episode psychosis. Schizophrenia Research, 2022, 246, 202-204.	2.0	0